Onvansertib Clinical Trials
4 recruitingDrug
Phase 22Phase 12Early Phase 11
Showing 1–4 of 4 trials
Recruiting
Early Phase 1
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
Stage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8+5 more
OHSU Knight Cancer Institute90 enrolled1 locationNCT04005690
Recruiting
Phase 1
Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms
Recurrent Chronic Myelomonocytic LeukemiaRefractory Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic/Myeloproliferative Neoplasm+3 more
Mayo Clinic25 enrolled1 locationNCT05549661
Recruiting
Phase 2
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
University of Maryland, Baltimore37 enrolled2 locationsNCT05450965
Recruiting
Phase 1Phase 2
Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer
Pancreatic Cancer
University of Kansas Medical Center21 enrolled1 locationNCT06736717